Of interest, a combined effect was observed by targeting GD2 ganglioside and AURKA in the inhibition of MYCN expression and induction of cell death in neuroblastoma cells [47] Collectively, these data suggest that targeting ganglioside synthesis is a promising therapeutic strategy for liver cancer. The gene discussed is MYCN; the disease is liver cancer.